In addition, mutant p53 evades Mdm2-mediated degradation by binding to Hsp90, but when geldanamycin (53) (Fig. 8), which is produced by Streptomyces actinomycetes, binds to Hsp90, mutant p53 is liberated from the complex and subsequently degraded by Mdm2 and CHIP, suppressing cancer progression [65]. The gene discussed is MDM2; the disease is cancer.